|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1011121314151617181920...4041» |
- ||| Enrollment open: MS-CARE: Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=200, Enrolling by invitation, Sponsor: University of Washington
Not yet recruiting --> Enrolling by invitation
- ||| Trial completion, Enrollment change, Trial primary completion date: TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS) (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=166, Completed, Sponsor: University of Washington
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed | N=120 --> 166 | Trial primary completion date: Sep 2013 --> Dec 2012
- |||| dalfampridine / Generic mfg.
Trial completion, Trial initiation date, HEOR: ENABLE: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (clinicaltrials.gov) - Apr 6, 2015
P4, N=901, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed | N=120 --> 166 | Trial primary completion date: Sep 2013 --> Dec 2012 Active, not recruiting --> Completed | Initiation date: Feb 2012 --> Feb 2013
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: REFINE: Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Apr 6, 2015
P2, N=291, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed | Initiation date: Feb 2012 --> Feb 2013 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change: Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) (clinicaltrials.gov) - Apr 6, 2015
P1/2, N=40, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=80 --> 40
- Enrollment change, Trial withdrawal: Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=0, Withdrawn, Sponsor: Genetic Disease Investigators
Recruiting --> Active, not recruiting | N=80 --> 40 N=25 --> 0 | Recruiting --> Withdrawn
- Trial completion: Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Apr 3, 2015
P2/3, N=14, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
N=25 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=60, Completed, Sponsor: Genetic Disease Investigators
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Apr 2015
- ||||| dimethyl fumarate / Generic mfg.
Enrollment closed: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Mar 31, 2015
P3, N=225, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Apr 2015 Recruiting --> Active, not recruiting
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 31, 2015
P4, N=63, Completed, Sponsor: Clinique Neuro-Outaouais
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment status: Gastroesophageal Reflux Treatment in Scleroderma (clinicaltrials.gov) - Mar 31, 2015
P3, N=250, Enrolling by invitation, Sponsor: Khon Kaen University
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Enrollment change, Trial initiation date: A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 27, 2015
P=N/A, N=79, Terminated, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Enrolling by invitation N=200 --> 79 | Initiation date: Mar 2007 --> Feb 2004
- Enrollment closed, Enrollment open: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Örebro County Council
N=200 --> 79 | Initiation date: Mar 2007 --> Feb 2004 Recruiting --> Active, not recruiting
- | Enrollment change: MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study (clinicaltrials.gov) - Mar 25, 2015
P3, N=279, Terminated, Sponsor: Institut fur Klinische Forschung, Germany
Recruiting --> Active, not recruiting N=400 --> 279
- |||| teriflunomide / Generic mfg.
Trial completion: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (clinicaltrials.gov) - Mar 25, 2015
P2, N=147, Completed, Sponsor: Sanofi
N=400 --> 279 Active, not recruiting --> Completed
- Trial completion: Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=180, Completed, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: Effects of Training on Central Auditory Function in Multiple Sclerosis (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=52, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed N=158 --> 52
- Enrollment closed: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (clinicaltrials.gov) - Mar 17, 2015
P1/2, N=8, Active, not recruiting, Sponsor: Germans Trias i Pujol Hospital
N=158 --> 52 Recruiting --> Active, not recruiting
- | Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Assessing Tolerability of Avonex Intramuscular Injections (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=20, Completed, Sponsor: Saint Francis Care
Recruiting --> Active, not recruiting Recruiting --> Completed
- | amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Comparative Oral Bioavailability Study of MT-1303 (clinicaltrials.gov) - Mar 17, 2015
P1, N=34, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Recruiting --> Completed
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Mass Balance Study of MT-1303 (clinicaltrials.gov) - Mar 17, 2015
P1, N=8, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=1000, Recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Aug 2015
- Trial primary completion date: Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA) (clinicaltrials.gov) - Mar 12, 2015
P1/2, N=63, Active, not recruiting, Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Trial primary completion date: Jun 2016 --> Aug 2015 Trial primary completion date: Oct 2014 --> Nov 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Mar 12, 2015
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Oct 2014 --> Nov 2015 Trial primary completion date: Jan 2015 --> May 2015
- | Trial completion, Enrollment change, Trial primary completion date: Neuromuscular Ultrasound in ALS (clinicaltrials.gov) - Mar 11, 2015
P=N/A, N=40, Completed, Sponsor: Duke University
Trial primary completion date: Jan 2015 --> May 2015 Active, not recruiting --> Completed | N=50 --> 40 | Trial primary completion date: Jul 2015 --> Mar 2015
- |||| ozanezumab (GSK 1223249) / GSK
Trial completion: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 11, 2015
P2, N=304, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=50 --> 40 | Trial primary completion date: Jul 2015 --> Mar 2015 Active, not recruiting --> Completed
- Betaseron (IFN-β-1b) / Bayer
Trial withdrawal: Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Mar 10, 2015
P3, N=0, Withdrawn, Sponsor: Bayer
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||||||| glatiramer acetate / Generic mfg.
Trial completion: Efficacy and Safety of GTR in Comparison to Copaxone® (clinicaltrials.gov) - Mar 10, 2015
P3, N=750, Completed, Sponsor: Synthon BV
Terminated --> Withdrawn Active, not recruiting --> Completed
- || vatelizumab (GBR 500) / Glenmark
Enrollment status: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Mar 9, 2015
P2, N=168, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Trial primary completion date, HEOR: PDMSLac: Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=39, Recruiting, Sponsor: Florida State University
Recruiting --> Enrolling by invitation Trial primary completion date: Nov 2014 --> Nov 2015
- baclofen / Generic mfg.
Enrollment change: CIBI: Continuous Intrathecal Baclofen Infusion for Chronic Spasticity (clinicaltrials.gov) - Mar 7, 2015
P3, N=0, Withdrawn, Sponsor: Flowonix Medical
Trial primary completion date: Nov 2014 --> Nov 2015 N=20 --> 0
- Vitaros (alprostadil + novel excipient) / Seelos Therap
Trial primary completion date: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Mar 7, 2015
P2, N=45, Recruiting, Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
N=20 --> 0 Trial primary completion date: Mar 2015 --> Jun 2015
- dalfampridine / Generic mfg.
Trial primary completion date: Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (clinicaltrials.gov) - Mar 7, 2015
P4, N=50, Recruiting, Sponsor: Clinique Neuro-Outaouais
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> Jul 2015
- cyclophosphamide / Generic mfg.
Enrollment change, Combination therapy: Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders (clinicaltrials.gov) - Mar 7, 2015
P1, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2014 --> Jul 2015 N=20 --> 6
- telbermin (sNN-0029) / Newron
Enrollment open: A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS (clinicaltrials.gov) - Mar 7, 2015
P1, N=18, Recruiting, Sponsor: Newron Sweden AB
N=20 --> 6 Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg.
Trial completion, Combination therapy: Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders (clinicaltrials.gov) - Mar 4, 2015
P1, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Mar 3, 2015
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Trial primary completion date: Jun 2018 --> Mar 2020
- Trial primary completion date: Study of Electrical Impedance Myography (EIM) in ALS (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=120, Recruiting, Sponsor: Skulpt, Inc.
Trial primary completion date: Jun 2018 --> Mar 2020 Trial primary completion date: Apr 2015 --> Oct 2015
- ||| Enrollment open: Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 2, 2015
P=N/A, N=200, Recruiting, Sponsor: University of Ulm
Trial primary completion date: Apr 2015 --> Oct 2015 Not yet recruiting --> Recruiting
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Feb 27, 2015
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Sep 2016
- ||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment closed: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Feb 27, 2015
P2, N=74, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=144, Recruiting, Sponsor: Niguarda Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment open, Trial primary completion date: Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=160, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2014 --> Jan 2017
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 23, 2015
P2, N=97, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2014 --> Jan 2017 Active, not recruiting --> Completed
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: COSTAN: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=150, Recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2017
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) - Feb 20, 2015
P4, N=90, Recruiting, Sponsor: EMD Serono
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Jan 2015 --> Nov 2015
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Enrollment change: Canadian Avonex PEN Productivity Study (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=111, Completed, Sponsor: Biogen Idec
Trial primary completion date: Jan 2015 --> Nov 2015 Recruiting --> Completed | N=500 --> 111
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) - Feb 20, 2015
P1, N=81, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed | N=500 --> 111 Recruiting --> Completed
- methylprednisolone sodium succinate / Generic mfg.
Trial primary completion date: Optic Neuritis Recovery After Oral or IV Corticosteroids (clinicaltrials.gov) - Feb 19, 2015
P2/3, N=46, Recruiting, Sponsor: London Health Sciences Centre
Recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2016
- arimoclomol (OR-01) / Orphazyme, KemPharm
Enrollment change: Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Feb 19, 2015
P2/3, N=39, Active, not recruiting, Sponsor: University of Miami
Trial primary completion date: Sep 2014 --> Sep 2016 N=80 --> 39